Several observational studies have shown that patients taking TNF inhibitors have a lower risk of cardiovascular events than patients using only conventional synthetic DMARDs (csDMARDs) in RA, AS, and PsA [69,70,71]. Here, TNF is linked to rheumatoid arthritis.